NanoViricides, Inc. (NNVC)
Chart Events
Performance Outlook
| Previous Close | 1.4900 |
| Open | 1.4500 |
| Bid | 1.4600 x 1100 |
| Ask | 1.5700 x 3000 |
| Day's Range | 1.5300 - 1.5300 |
| 52 Week Range | 1.0400 - 7.8600 |
| Volume | |
| Avg. Volume | 37,240 |
| Market Cap | 17.647M |
| Beta (5Y Monthly) | 0.87 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7660 |
| Earnings Date | Nov 16, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.50 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for NNVC
Related Research
- NanoViricides, Inc.Technical Assessment: Bearish in the Intermediate-TermVolatility in West Texas Intermediate (WTI) crude oil has started to shrink a bit, with the recent range between the high $90s and $110 and with WTI currently sitting at $105/barrel. After going parabolic in March and reaching $130, crude oil pulled back to $93.50, rallied back to $116.65, and fell to an intraday low of $93 on April 11 before rallying back above $107. It is still possible that WTI is tracing out symmetrical triangle, although the past breakout attempt in early May failed.RatingFair ValueEconomic Moat6 days agoArgus Research
- ACCESSWIRE
NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2022 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Progressing Further for Clinical Trials Application
SHELTON, CT / ACCESSWIRE / May 17, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, has filed the quarterly report for third quarter of its 2022 fiscal year with the Securities and Exchange Commission.
- Benzinga
NanoViricides Starts Drug Development Program For Recent Cases Of Unexplained Pediatric Hepatitis
NanoViricides Inc (NYSE: NNVC) has initiated a program to screen its library of broad-spectrum antiviral nanoviricides against human Adenovirus 41 Type F (hAd41-F), believed to be strongly associated with the occurrence of severe hepatitis syndrome in some children. The company says its top priority remains to initiate human trials of its SARS-CoV-2 drug candidate NV-CoV-2 to combat COVID-19. NanoViricides expects filing a clinical trial application for COVID-19 to occur relatively soon, althoug
- ACCESSWIRE
NanoViricides Reports that It Has Begun Drug Development to Combat Recent Cases of Severe Pediatric Hepatitis
SHELTON, CT / ACCESSWIRE / May 16, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform reports that it has begun drug development to combat recent cases of severe pediatric hepatitis.
